Reactive Oxygen Therapeutics
Treating inflammation without supressing immune system.
Achievements
Team
Prototype
Users
Partners
Revenue
Investors
What we offer
We offer new type of treatment against autoimmune diseases.
Our Story
ROT is an early-stage pre-seed start-up. We are dedicated to the treatment of health conditions triggered or accompanied by oxidative stress (OS), such as autoimmune diseases and cancer. Our innovative approach will utilize a novel small molecule prodrug strategy, which is built upon OS-inducing molecular catalysts. These prodrugs are meticulously designed to activate exclusively within cells already experiencing oxidative stress, thereby addressing the patient's condition without causing harm to healthy tissues. The modular design of the prodrugs lets us attach any drug and significantly boost its selectivity toward cancerous tissue and activated myeloid cells (responsible for inflammatory boost).
We already have one drug candidate able to resolve inflammation in autoimmune conditions by selectively generating OS in already activated but compromised neutrophils. Healthy cells stay unaffected. This drug can potentially be used against rheumatoid arthritis, chronic granulomatous disease, and gout.
The company is a spin-off from Friedrich-Alexander-Universität Erlangen-Nürnberg. The main work and discovery were done in the NeutroCure project (https://www.neutrocure.eu/). The new drugs were developed in Erlangen and tested by all colleagues from Germany, Spain, UK, Sweden. We are preparing to apply for EXIST-Forschungstransfer to do preliminary toxicology study and scout for optimized structures of our drug, as well as to prepare for VC funding.
We already have one drug candidate able to resolve inflammation in autoimmune conditions by selectively generating OS in already activated but compromised neutrophils. Healthy cells stay unaffected. This drug can potentially be used against rheumatoid arthritis, chronic granulomatous disease, and gout.
The company is a spin-off from Friedrich-Alexander-Universität Erlangen-Nürnberg. The main work and discovery were done in the NeutroCure project (https://www.neutrocure.eu/). The new drugs were developed in Erlangen and tested by all colleagues from Germany, Spain, UK, Sweden. We are preparing to apply for EXIST-Forschungstransfer to do preliminary toxicology study and scout for optimized structures of our drug, as well as to prepare for VC funding.
Team
